文献速递自身炎症与 IgG4 相关病

NIH「All of Us」队列245368名多样个体中定义VEXAS的UBA1体细胞变异

VEXAS-Defining UBA1 Somatic Variants in 245,368 Diverse Individuals in the NIH All Of Us Cohort.
PubMed 文献 · Arthritis Rheumatol · 2024-02-29

在All of Us研究计划245368名参与者的临床级全基因组测序数据中,识别出74名携带UBA1 c.121A>C(p.Met41Leu)体细胞变异者,等位基因分数4.5%–33%,未发现其他经典VEXAS相关变异。病例对照分析未发现该变异与任何VEXAS相关诊断编码、药物处方或实验室值存在统计学显著关联,提示该变异对VEXAS外显不全。

要点

  • 在245368名多样人群中检出74名携带UBA1 p.Met41Leu体细胞变异者,等位基因分数4.5%–33%。
  • 74名携带者中62名(84%)为女性,20名(27%)为非裔美国人,14名(19%)为American Admixed/Latino。
  • 病例对照分析未发现该变异与任何VEXAS相关诊断编码、药物处方或实验室值存在统计学显著关联。

核心结论

  • UBA1 p.Met41Leu体细胞变异对VEXAS显示外显不全。
  • 需进一步研究以确定VEXAS相关体细胞变异在疾病前期的自然史。

研究设计与样本

  • 分析All of Us研究计划245368名参与者的临床级全基因组测序数据。
  • 将携带经典VEXAS相关体细胞变异者与按年龄、性别和祖先匹配的对照进行比较,比较领域包括诊断、药物和实验室值。

主要发现

  • 共识别74名携带一个VEXAS定义性体细胞变异UBA1 c.121A>C(p.Met41Leu)的参与者,等位基因分数范围为4.5%至33%。
  • 未识别出其他经典VEXAS相关变异。
  • 74名携带者中62名(84%)为女性,20名(27%)为非裔美国人,14名(19%)为American Admixed/Latino。
  • 病例/对照状态与任何VEXAS相关诊断编码、药物处方或实验室值之间均无统计学显著关联。
  • 该队列与已报道的临床VEXAS患者队列存在实质性差异,年轻、女性和多样祖先个体的比例更高,等位基因分数低于临床VEXAS队列的报道值,生物信息学分析未检测到VEXAS的临床表现。

关键数值与推荐

  • VEXAS定义性体细胞变异为UBA1 c.121A>C(p.Met41Leu)。
  • 74名携带者的等位基因分数范围为4.5%至33%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步研究以确定VEXAS相关体细胞变异在疾病前期的自然史。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Somatic variants in UBA1 cause VEXAS, a recently described, systemic autoinflammatory disease. Research on VEXAS has largely focused on highly symptomatic patients. We sought to determine the prevalence of canonical, VEXAS-associated somatic variants and their disease penetrance in a diverse, unselected population. METHODS: We analyzed clinical-grade whole genome sequencing data from 245,368 participants in the All of Us Research Program. We compared persons carrying a canonical VEXAS-associated somatic variant to age, sex, and ancestry matched controls across the domains of diagnoses, medications, and laboratory values. RESULTS: 74 participants were identified who carry one VEXAS-defining somatic variant, UBA1 c.121A>C, p.Met41Leu. The variant allele fraction ranged from 4.5% to 33%. No other canonical VEXAS-associated variants were identified. Of the 74 carriers, 62 (84%) were women, 20 (27%) were African American, and 14 (19%) were American Admixed/Latino. There was no statistically significant association between case/control status and any VEXAS-associated diagnosis code, medication prescription, or laboratory value. CONCLUSION: We report the largest cohort to date of persons with the VEXAS-associated p.Met41Leu somatic variant. This cohort differed substantially from reported cohorts of patients with clinical VEXAS, having a higher proportion of persons who were young, female, and of diverse ancestry. Variant allele fractions were lower than reported in clinical VEXAS cohorts, and bioinformatic analysis detected no clinical manifestations of VEXAS. Thus, the UBA1 p.Met41Leu somatic variant displayed incomplete penetrance for VEXAS. Further study is needed to determine the natural history of VEXAS-associated somatic variants in the predisease phase.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Corty RW, Brogan J, Byram K, et al. VEXAS-Defining UBA1 Somatic Variants in 245,368 Diverse Individuals in the NIH All Of Us Cohort. Arthritis Rheumatol. 2024. PMID: 38225170. doi:10.1002/art.42802

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。